Drug updated on 9/4/2024
Dosage Form | Implant (subcutaneous; 16 mg) |
Drug Class | Melanocortin receptor agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
Latest News
Summary
- Scenesse (afamelanotide) is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Afamelanotide (Scenesse) demonstrated a moderate positive effect in reducing skin photosensitivity in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), as observed in controlled trials.
- Inorganic sunscreen also showed a moderate positive effect in controlled trials, whereas organic sunscreen, beta-carotene, cysteine, N-acetylcysteine, vitamin C, and warfarin showed no effect in similar trials.
- Treatments such as foundation cream, dihydroxyacetone/lawsone cream, and others suggested potential effectiveness in uncontrolled studies, but the actual effects remain uncertain due to the lack of control and possible bias.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Scenesse (afamelanotide) Prescribing Information. | 2020 | Clinuvel Inc., Burlingame, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: a systematic review. | 2023 | Biomedicine & Pharmacotherapy |